Compare

Swedish Orphan Biovitrum AB/Skr SOBI

1D1W1M3M6MYTD1Y5YMAX

About Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB is a biotechnology company primarily focused on developing and commercializing specialty pharmaceuticals for rare diseases. The company is active in therapeutics for hematology, immunology, and genetic and metabolic disorders. Swedish Orphan Biovitrum was founded in 2001 and is headquartered in Stockholm, Sweden. The company operates globally, reaching markets in Europe, North America, and other regions. A key aspect of its strategic positioning is its commitment to addressing unmet medical needs in rare diseases, which often provides a unique market niche. The company invests significantly in research and development to fuel growth and innovation in its therapeutic areas.
Ticker
Skr SOBI
Sector
Health
Primary listing
XSTO
Employees
2,207
Headquarters
Stockholm, Sweden
Website
www.sobi.com

SOBI Metrics

BasicAdvanced
kr 171B
26.03
kr 18.80
0.36
-

What the Analysts think about SOBI

Analyst ratings (Buy, Hold, Sell) for Swedish Orphan Biovitrum AB stock.
Analyst projections of the future price of Swedish Orphan Biovitrum AB stock.

Bulls say / Bears say

Sobi raised its 2026 revenue-growth outlook to high teens to low 20s at constant exchange rates after year-to-date growth of 23%. Q3 revenue rose 16% at constant exchange rates, giving the upgrade recent operating support. (Swedish Orphan Biovitrum AB)
Altuvoct is scaling quickly: Q3 sales more than doubled year on year to SEK 1.73 billion, and Sobi says the launch has reached 32 countries with further rollout stages ahead. That gives the company a product-specific growth driver beyond its established portfolio. (Swedish Orphan Biovitrum AB, Investing.com)
Sobi’s Tryngolza received a positive European regulatory opinion for severe hypertriglyceridaemia, paving the way for a potential 2027 launch into a larger patient market. Separately, its gout candidate pozdeutinurad met the primary endpoint in a pivotal Phase 3 study, adding another possible future growth source. (Swedish Orphan Biovitrum AB, Sobi)
The FDA issued a complete response letter for NASP, requesting more manufacturing-control data and remediation at a contract facility. This delays a potential US launch, and Sobi has not yet set a clear resubmission timetable. (PR Newswire)
CEO Guido Oelkers is due to leave by January 2027, while Sobi carries about SEK 15 billion of net debt after major portfolio deals. The handover matters because its growth plan depends in part on buying and successfully commercialising external medicines. (European Biotechnology Magazine, Swedish Orphan Biovitrum AB)
Profitability is facing pressure as launch and research spending rises: Sobi’s Q3 adjusted EBITA margin fell to 45% from 47% a year earlier, while operating expenses increased 24% at constant exchange rates. The company expects further investment in launches and development in Q4. (Swedish Orphan Biovitrum AB, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.

SOBI Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

SOBI Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing SOBI

AllEURUSDGBP
Funds
Fund name
Fund size
Skr SOBI weighting
iShares STOXX Europe Mid 200€EXSD
€610M0.63%
Xtrackers MSCI Nordic£XDN0
€1.1B0.59%
iShares STOXX Europe 600 Health Care€EXV4
€709M0.58%
iShares Ageing Population$AGED
$953M0.52%
iShares Ageing Population€AGED
$903M0.52%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.